press releases

Date Title  
02/18/20
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positive
 
02/05/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference , Wednesday, February 26 , at 2:30 p.m.
 
01/13/20
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.